Search alternatives:
026 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
026 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2181
-
2182
Exposures to PM<sub>2.5</sub>, PM<sub>10</sub> and Nitrogen dioxide.
Published 2024“…The vast majority (96%) of hip fracture units were located in zones where mean PM<sub>2.5</sub> levels exceeded that required by the WHO guidance. …”
-
2183
SIRT5 is a proviral factor.
Published 2022“…<b>E</b>. Decrease in cell-associated viral mRNA levels in A549-ACE2 cells infected with SARS-Cov-2 for 3 days at MOI = 0.1, and treated with SIRT5 and SIRT1 inhibitors Sirt5-i and Ex-527, as shown by RT-qPCR. …”
-
2184
-
2185
-
2186
-
2187
-
2188
-
2189
-
2190
-
2191
-
2192
-
2193
Effects of Cyr61 and Wnt5a on regenerating vasculature and musculature.
Published 2015“…(B) Wnt5aOX demonstrated mean muscle content most comparable to MSC/CD34<sup>+</sup> HSPC grafts [percent red (muscle): (red (muscle) pixels / red (muscle) + blue (collagen) pixels)]. (§ Unseeded, MSC and MSC/CD34<sup>+</sup> HSPC data, shown as solid and dotted lines, previously reported [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138643#pone.0138643.ref007" target="_blank">7</a>]). …”
-
2194
-
2195
Mean SARS-CoV-2 viral load log 10 between groups.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
2196
Mean (± Standard Error) relative distribution (%) of the energy contained in the signal up to 200 Hz as a function of the frequency bands on the X-, Y- and Z-axis of the racket accelerometer (XR, YR and ZR, respectively) and X-axis of the wrist accelerometer (XW), for both decreased (V-) and increased (V+) velocity conditions (left), and for both lightly vibrant (RL) and highly vibrant (RH) rackets (right), with * for p≤0.05, ** for p ≤ 0.01, and *** for p ≤ 0.001.
Published 2015“…<p>Mean (± Standard Error) relative distribution (%) of the energy contained in the signal up to 200 Hz as a function of the frequency bands on the X-, Y- and Z-axis of the racket accelerometer (XR, YR and ZR, respectively) and X-axis of the wrist accelerometer (XW), for both decreased (V-) and increased (V+) velocity conditions (left), and for both lightly vibrant (RL) and highly vibrant (RH) rackets (right), with * for p≤0.05, ** for p ≤ 0.01, and *** for p ≤ 0.001.…”
-
2197
-
2198
-
2199
The mean and standard deviation of parameters.
Published 2024“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”
-
2200